Reading the tape
NASDAQ: PACB
Pacific Biosciences of California, Inc.
Healthcare · Medical - Devices
Market Cap
$468.10M
52w High
$2.73
52w Low
$0.85
P/E
-0.86
Volume
3.60M
Outstanding Shares
302.00M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 39.64%Revenue (TTM): 3.89%FCF (TTM): 41.61%P/S: 15th pct
What changed
The stock rose 39.64% over the last year. Revenue grew 3.89% over the trailing twelve months. Operating margin moved from -307.97% to -346.11%. Free cash flow grew 41.61% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 15th percentile of their historical P/S range.
What would invalidate this read
Operating margin is at -346.11%. Revenue grew 3.89% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems.
CEOChristian O. Henry
SectorHealthcare
IndustryMedical - Devices
Employees575
IPO dateOct 27, 2010
Valuation
Forward P/E—
EV/EBITDA-36.75
Enterprise value$1.26B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth13.82%
Gross margin28.21%▲30.83%vs FY2024
Operating margin-346.11%▼13.15%vs FY2024
ROE-10,214.54%▼16600.37%vs FY2024
Analyst consensus
RatingBuy
Target price$1.00▼35.48%
9
Buy
8
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.17 · Revenue est $39.95M
View